ZONTIVITY
Commercial- Indications
- Myocardial infarction, Peripheral arterial disease
Company intelligence / Profile preview
WraSer Pharmaceuticals
Ridgeland, Mississippi, United Statescience.com ↗
- Ownership
- Private
- Employees
- ~26
- Development stage
- Commercial
01
Overview
WraSer Pharmaceuticals markets FDA-approved products across multiple therapeutic areas including cardiovascular, otic, and pain management. In 2023, six of their FDA-approved assets were acquired by Blue Water Biotech for $8.5 million.
- Therapeutic areas
- CardiovascularNeurologyInfectious Diseases
- Modalities
- Small molecules
- Industry
- Biotech
02
Drug pipeline
6 assets5 more assets in the full pipeline.
Request access →03
Partnerships
Blue Water Biotech (acquisition of assets)
Beyond the preview
Go deeper on WraSer Pharmaceuticals.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on WraSer Pharmaceuticals.